

# Multi Cancer Early Diagnostics

Inspire2Live and SeekIn collaboration



# Inspire2Live congress 2022




Khama Rogo: "4 chairs" presentation



**Low-cost cancer detection: OncoSeek®**

OncoSeek®, a combination of 7 clinically validated plasma tumor markers (AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1), using a new multivariate OncoSeek algorithm combined with big data and AI, performs early detection for 12 common cancers by calculating the probability of cancer (POC) and tracing the cancer tissue of origin (TOO).

CE Marking 


Bladder Breast Cervix Colorectum Esophagus Gallbladder  
Liver Lung Ovary Pancreas Stomach Testis

plasma

Protein marker panel


Machine learning

POC  
TOO



Mao Mao: SeekIn MCED based on blood sample

# What causes delays in cancer diagnosis and treatment?



Our aim to reduce the time between 1st symptom and diagnosis as much as possible

# Inspire2Live – SeekIn collaboration

Objective to make SeekIn products available to as many people as possible (as soon as possible)

**=> focus on OncoSeek**

**Biggest benefit especially in LMIC**

- **Low cost**
- **High specificity and sensitivity**
- **Leveraging existing medical infrastructure**

# Inspire2Live – SeekIn collaboration

Today: signed legal agreement as official partner of SeekIn  
Separate legal entity “Oncolnv” fully owned by Inspire2Live

- LMIC at cost price
- Any profit for shareholders (I2L)

Current status:

- Available in Bulgaria soon (expected 1st quarter 2024)
- Kenya
  - Grant application for study in Kisumu (Arthur Ajwang) with Prevent Cancer Foundation
  - Talks with private hospital
- Discussions with IARC on studies in India and China
- Discussions with Dutch hospitals on further study treatment monitoring and possible early diagnosis with GPs

..... (much) more to come as Oncolnv will be expanding quickly in coming months

**we need your help and support in helping us connect with the right people in your country**